The Mumbai-based Advanced Enzyme Technologies Limited (AETL), India's one of the leading biotechnology company specialised in the enzyme research and development, caters to the needs of the healthcare as well as the processing industry.

The company, established in 1989 by C L Rathi, has an investment of over USD $10 million. It produces enzymes and probiotics worth more than USD $20 million annually. The company has a turnover of over Rs 75 crore and is claimed as the only Indian company, which provides customised solutions using enzyme technology.

According to Advanced Enzyme Technologies, the company's vision is to treat and prevent the underlying cause of disease as well as replace conventional procedures that usually consist of harsh chemicals, with enzyme based solutions, which have no side effects. In the healthcare sector the spectrum of services includes pharmaceuticals nutraceuticals and animal healthcare.

With a global presence of more than 30 countries, AETL is one of the few companies, which engages in the commercial production of probiotics (the 'beneficial' or 'good' micro-organisms), sources added.

The company spends 10 per cent of its sales revenue for the development of new enzymes and application activities to develop a full spectrum of healthcare enzymes that primarily originate from biological systems. The company has so far filed for 5 patents in pharmaceuticals and is currently working on a novel drug delivery system.

The company's state of the art manufacturing facility, located in Nasik, possesses the ISO 9001:2000 and WHO cGMP certification. Its group companies, Specialty Enzymes and Biochemicals Co (SEB) and Speciality Enzymes Europe (SEE) cater to the needs of the American, European and African markets respectively. The company also focuses on animal healthcare, environment care and agriculture.